In a meta-analysis, researchers evaluated the diagnostic accuracy of circulating miRNAs in the diagnosis of PD.
Highlights from AHS 2022 include use of ubrogepant plus onabotulinumtoxinA for breakthrough migraines, eptinezumab for migraine prevention, and vagal nerve stimulation to treat visual snow.
The RELEASE MSS1 trial included adults with a confirmed diagnosis of any disease subtype of multiple sclerosis.
Although not bound by the committee’s recommendations, the Agency does take them into consideration when making decisions on approval.
Crenezumab is an investigational monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid.
The oral suspension can be administered by mouth or via feeding tube using a 5mL oral syringe that comes with the product.
Presenting at AHS 2022, researchers examined the effects of supplementation of B vitamins and a combination of these vitamins on women with episodic migraine.
The FDA extended the action date by 3 months to allow more time to review additional analyses of data from the Company’s clinical studies.
In a quantitative study, researchers assessed the efficacy of TMS on depressive symptoms in people with MS.
Investigators assessed the relationship between sleep architecture and circadian rhythm in patients with ASD using dim light melatonin onset (DLMO) and ambulatory polysomnography.
Presenting at CMSC 2022, researchers evaluated the prognostic value of baseline NfL for predicting clinical relapse and change in MRI lesion activity among patients with MS.
In a meta-analysis, researchers examined the efficacy of yoga therapy as a treatment for patients with migraine.
The approval was based upon a bioavailability study in healthy adults comparing baclofen oral tablets to Lyvispah.
In a clinical trial, researchers assessed the effect of mental practice on mobility rehabilitation in the early subacute phase after stroke compared with a control group.
The NDA submission includes data from 2 pivotal studies that evaluated zavegepant in adults with at least a 1-year history of migraine and migraine attacks.
Researchers sought to compare the efficacy of a standard version of an internet-delivered CBT-I program, a culturally tailored version, and a sleep education control at improving insomnia symptoms.
This systematic review did not find any high quality evidence supporting the use of injectable biologics for neuropathic pain.
Analiz Rodriguez, MD, a neurosurgeon in Arkansas, recounts her experience with misogynoir during her residency training and the toll it took on her as a Black woman.
In a large, prospective cohort study, researchers assessed the association between daily total physical activity and the risk of developing disabling dementia in the general Japanese population.
In a prospective cohort study, researchers assessed whether adverse childhood experiences may increase the risk for multiple sclerosis in women.